Guardant Health (NASDAQ:GH) Shares Up 3.4%

Shares of Guardant Health, Inc. (NASDAQ:GH) were up 3.4% during trading on Wednesday . The company traded as high as $16.88 and last traded at $16.71. Approximately 786,617 shares changed hands during trading, a decline of 58% from the average daily volume of 1,890,139 shares. The stock had previously closed at $16.16.

Analyst Ratings Changes

Several research analysts recently weighed in on GH shares. The Goldman Sachs Group cut their target price on Guardant Health from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday. Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a report on Friday, April 5th. Piper Sandler decreased their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, February 26th. Canaccord Genuity Group dropped their price target on shares of Guardant Health from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, February 23rd. Finally, JPMorgan Chase & Co. cut their target price on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.40.

Guardant Health Trading Up 2.9 %

The company has a current ratio of 6.54, a quick ratio of 6.24 and a debt-to-equity ratio of 7.18. The stock’s 50-day simple moving average is $19.57 and its 200-day simple moving average is $23.45.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). The firm had revenue of $155.05 million during the quarter, compared to the consensus estimate of $151.71 million. Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. On average, analysts forecast that Guardant Health, Inc. will post -3.49 earnings per share for the current year.

Insider Transactions at Guardant Health

In related news, insider Kumud Kalia acquired 2,187 shares of the business’s stock in a transaction on Monday, March 18th. The stock was acquired at an average cost of $17.82 per share, with a total value of $38,972.34. Following the acquisition, the insider now directly owns 12,722 shares in the company, valued at approximately $226,706.04. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 6.20% of the company’s stock.

Institutional Trading of Guardant Health

Several institutional investors and hedge funds have recently made changes to their positions in GH. CWM LLC grew its stake in shares of Guardant Health by 137.1% during the third quarter. CWM LLC now owns 984 shares of the company’s stock worth $29,000 after acquiring an additional 569 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Guardant Health by 33.2% in the 2nd quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock worth $44,000 after acquiring an additional 271 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Guardant Health in the 3rd quarter worth $35,000. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new stake in shares of Guardant Health during the 1st quarter worth about $89,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Guardant Health during the 1st quarter worth about $37,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.